IL32 and cancer: Our results also provide potentially new mechanistic insight into the role of IL-32, demonstrating that myeloid cells but not lymphocytes or cancer cells respond to IL-32 treatment by activating the MAPK/ERK pathway, suggesting its binding to a hitherto unidentified surface receptor.